Home » Stocks » Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. (IDRA)

Stock Price: $2.04 USD -0.09 (-4.23%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $1.92 -0.12 (-5.88%) Aug 4, 7:41 PM

Stock Price Chart

Key Info

Market Cap 68.90M
Revenue (ttm) 1.45M
Net Income (ttm) -36.72M
Shares Out 34.53M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $2.04
Previous Close $2.13
Change ($) -0.09
Change (%) -4.23%
Day's Open 2.13
Day's Range 2.00 - 2.14
Day's Volume 175,708
52-Week Range 0.81 - 3.58

More Stats

Market Cap 68.90M
Enterprise Value 36.44M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.53M
Float 24.93M
EPS (basic) -2.3
EPS (diluted) -2.27
FCF / Share -1.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 425,941
Short Ratio 2.41
Short % of Float 1.57%
Beta 2.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 47.59
PB Ratio 1.24
Revenue 1.45M
Operating Income -47.84M
Net Income -36.72M
Free Cash Flow -41.90M
Net Cash 32.47M
Net Cash / Share 0.96
Gross Margin -1,663.74%
Operating Margin -3,304.07%
Profit Margin -4,472.90%
FCF Margin -2,893.65%
ROA -60.30%
ROE -132.27%
ROIC 258.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.60*
(272.55% upside)
Low
5.00
Current: $2.04
High
10.00
Target: 7.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.450.660.9016.200.250.070.050.050.0516.11
Revenue Growth118.73%-26.61%-94.43%6405.62%241.1%55.32%-7.84%-3.77%-99.67%-
Gross Profit1.450.660.9016.200.250.070.050.050.0516.11
Operating Income-46.07-60.96-66.47-38.76-48.85-38.75-18.17-19.90-25.86-17.98
Net Income-56.52-59.88-65.98-38.39-48.56-38.64-18.23-19.24-23.78-17.96
Shares Outstanding28.5526.6019.6815.9514.3910.355.493.453.453.14
Earnings Per Share-2.96-2.25-3.35-2.41-3.36-3.76-3.84-6.48-8.24-5.68
Operating Cash Flow-44.50-51.92-55.26-28.20-42.99-31.32-17.14-19.92-19.19-19.56
Capital Expenditures-0.22-0.21-0.41-0.73-1.09-0.01--0.02-0.09
Free Cash Flow-44.50-51.70-55.47-28.61-43.71-32.41-17.15-19.92-19.22-19.65
Cash & Equivalents42.7971.4311310960.1641.2329.4010.4124.8834.95
Total Debt1.06-0.210.500.760.87----
Net Cash / Debt41.7371.4311210959.4040.3629.4010.4124.8834.95
Assets47.4973.0211811392.2851.4336.8710.8225.6036.88
Liabilities58.669.0310.729.888.698.024.424.207.653.78
Book Value-11.1763.9910810383.5843.4032.450.7112.0233.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Idera Pharmaceuticals, Inc.
Country United States
Employees 36
CEO Vincent J. Milano

Stock Information

Ticker Symbol IDRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IDRA
IPO Date January 24, 1996

Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.